{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:59:07Z","timestamp":1774292347061,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.psyneuen.2005.12.006","type":"journal-article","created":{"date-parts":[[2006,2,21]],"date-time":"2006-02-21T07:15:04Z","timestamp":1140506104000},"page":"577-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine"],"prefix":"10.1016","volume":"31","author":[{"given":"Bruce J.","family":"Kinon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonna","family":"Ahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Liu-Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald A.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psyneuen.2005.12.006_bib1","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiat."},{"issue":"6","key":"10.1016\/j.psyneuen.2005.12.006_bib2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocrinol. Rev."},{"issue":"1","key":"10.1016\/j.psyneuen.2005.12.006_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02238717","article-title":"Bromocriptine and psychosis: a literature review","volume":"66","author":"Boyd","year":"1995","journal-title":"Psychiatry Q."},{"issue":"3","key":"10.1016\/j.psyneuen.2005.12.006_bib5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000180094","article-title":"Hyperprolactinemia and sexual function in men","volume":"22","author":"Buvat","year":"1985","journal-title":"Horm. Res."},{"issue":"1","key":"10.1016\/j.psyneuen.2005.12.006_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-1781(02)00123-3","article-title":"Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder","volume":"111","author":"Canuso","year":"2002","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.psyneuen.2005.12.006_bib7","first-page":"143","article-title":"Antipsychotic-associated hyperprolactinemia and sexual dysfunction","volume":"36","author":"Compton","year":"2002","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.psyneuen.2005.12.006_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","article-title":"The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations","volume":"26","author":"Crawford","year":"1997","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.psyneuen.2005.12.006_bib9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effect of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clin. Ther."},{"issue":"Suppl.","key":"10.1016\/j.psyneuen.2005.12.006_bib10","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0920-9964(98)00159-5","article-title":"Neuroleptic-induced hyperprolactinemia","author":"Dickson","year":"1999","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.psyneuen.2005.12.006_bib11","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1176\/ajp.152.7.1102b","article-title":"Risperidone-induced prolactin elevations in premenopausal women with schizophrenia","volume":"152","author":"Dickson","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2005.12.006_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini mental state: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatry Res."},{"issue":"1","key":"10.1016\/j.psyneuen.2005.12.006_bib13","first-page":"71","article-title":"Variability of serum prolactin and progesterone levels in normal women: the relevance of single hormone measurements in the clinical setting","volume":"76","author":"Fujimoto","year":"1990","journal-title":"Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.psyneuen.2005.12.006_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00004714-199812000-00015","article-title":"Return of menstruation after switching from risperidone to olanzapine","volume":"18","author":"Gazzola","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2005.12.006_bib15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00005053-198208000-00004","article-title":"Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients","volume":"170","author":"Ghadirian","year":"1982","journal-title":"J. Nerv. Ment. Disord."},{"issue":"4","key":"10.1016\/j.psyneuen.2005.12.006_bib16","first-page":"296","article-title":"An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder","volume":"18","author":"Goff","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2005.12.006_bib18","series-title":"ECDEU Assessment Manual for Psychopharmacology: Publication Adm 76\u2013338","first-page":"534","year":"1976"},{"key":"10.1016\/j.psyneuen.2005.12.006_bib19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00006842-199509000-00011","article-title":"Decreased bone mineral density in medicated psychiatric patients","volume":"57","author":"Halbreich","year":"1995","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.psyneuen.2005.12.006_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2005.12.006_bib21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2005.12.006_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotics action","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.psyneuen.2005.12.006_bib23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood\u2013brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.psyneuen.2005.12.006_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.psyneuen.2005.12.006_bib25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4158\/EP.6.6.425","article-title":"Risperidone-associated hyperprolactinemia","volume":"6","author":"Kearns","year":"2000","journal-title":"Endocr. Pract."},{"issue":"5","key":"10.1016\/j.psyneuen.2005.12.006_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4088\/JCP.v63n0506","article-title":"Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone","volume":"63","author":"Kim","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2005.12.006_bib27","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4088\/JCP.v61n1105","article-title":"Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine","volume":"61","author":"Kinon","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2005.12.006_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2005.12.006_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","article-title":"Prolactin levels and adverse events in patients treated with risperidone","volume":"19","author":"Kleinberg","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2005.12.006_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0306-4530(02)00130-0","article-title":"What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?","volume":"28","author":"Knegtering","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"10.1016\/j.psyneuen.2005.12.006_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archpsyc.1976.01770030003001","article-title":"The effect of neuroleptics on serum prolactin in schizophrenic patients","volume":"33","author":"Meltzer","year":"1976","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.psyneuen.2005.12.006_bib33","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1176\/ajp.136.12.1550","article-title":"Effect of clozapine on human serum prolactin levels","volume":"136","author":"Meltzer","year":"1979","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2005.12.006_bib34","first-page":"249","article-title":"Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response","volume":"41","author":"Meltzer","year":"1983","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psyneuen.2005.12.006_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"issue":"12","key":"10.1016\/j.psyneuen.2005.12.006_bib36","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4088\/JCP.v63n1206","article-title":"Predictors of noncompliance in patients with schizophrenia","volume":"63","author":"Perkins","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl.","key":"10.1016\/j.psyneuen.2005.12.006_bib37","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1016\/S0924-9338(97)89490-4","article-title":"Sexual dysfunction: the unspoken side effect of antipsychotics","volume":"13","author":"Peuskens","year":"1998","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.psyneuen.2005.12.006_bib38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000118610","article-title":"Effects of treatment with various dose of haloperidol on the pituitary-gonadal azis in male schizophrenic patients","volume":"22","author":"Rinieris","year":"1989","journal-title":"Neuropsychobiology"},{"issue":"Suppl.","key":"10.1016\/j.psyneuen.2005.12.006_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand."},{"issue":"6","key":"10.1016\/j.psyneuen.2005.12.006_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo","volume":"54","author":"Small","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.psyneuen.2005.12.006_bib41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","article-title":"The effects of antipsychotic-associated hyperprolactinemia on the hypothalamic-pituitary-gonadal axis","volume":"22","author":"Smith","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2005.12.006_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psyneuen.2005.12.006_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","article-title":"Elevation of prolactin levels by atypical antipsychotics","volume":"159","author":"Turrone","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psyneuen.2005.12.006_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.psyneuen.2005.12.006_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/096120339500400102","article-title":"Prolactin: a stimulator of disease activity in systemic lupus erythematosus","volume":"4","author":"Walker","year":"1995","journal-title":"Lupus"},{"key":"10.1016\/j.psyneuen.2005.12.006_bib46","first-page":"951","article-title":"Prolactin and murine mammary tumorigenesis: a review","volume":"37","author":"Welsch","year":"1977","journal-title":"Cancer Res."},{"key":"10.1016\/j.psyneuen.2005.12.006_bib47","series-title":"Sexual Pharmacology","first-page":"1","article-title":"Pharmacological targets for the control of male and female sexual behavior","author":"Wilson","year":"1993"}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453005002544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453005002544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T16:27:45Z","timestamp":1759681665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453005002544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0306453005002544"],"URL":"https:\/\/doi.org\/10.1016\/j.psyneuen.2005.12.006","relation":{},"ISSN":["0306-4530"],"issn-type":[{"value":"0306-4530","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psyneuen.2005.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}